Drug Trial Radar · NCT02348489
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
815
Actual
Start
Mar 19, 2015
Primary completion
May 31, 2018
Study completion Jun 17, 2019
Sponsor
- Lead sponsor
- Astex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
Conditions
- Leukemia, Myeloid, Acute
Interventions
SGI-110 (guadecitabine)Drug
Investigational medicinal product
Treatment ChoiceDrug
Choice of one: cytarabine, decitabine, or azacitidine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Complete Response (CR)Time frame: Up to 38 months (median follow-up of 25.5 months)
- Overall SurvivalTime frame: At 676 death events (up to 38 months)
Locations
135 sites in 24 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Scottsdale, Arizona
Scripps Cancer Center
La Jolla, California
University of Southern California
Los Angeles, California
University of Chicago
Chicago, Illinois
University of Kansas Medical Center
Westwood, Kansas
University of Minnesota Medical Center
Minneapolis, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota
John Theurer Cancer Center at Hackensack
Hackensack, New Jersey
University of New Mexico Cancer Center
Albuquerque, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medical College
New York, New York
Columbia University Medical Center
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Duke Cancer Center
Durham, North Carolina
University Hospitals of Cleveland
Cleveland, Ohio
University Hospitals Monarch Medical Center
Cleveland, Ohio
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Temple University
Philadelphia, Pennsylvania
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
University of Wisconsin
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Hanusch Krankenhaus Wiener Gebietskrankenkasse
Vienna, State of Vienna, Austria
Medizinische Universität Graz
Graz, Styria, Austria
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
UZ Gent
Ghent, Oost-vlaanderen, Belgium
Algemeen Ziekenhuis Sint-Jan
Bruges, West-vlaanderen, Belgium
UMHAT 'Sveti Georgi' EAD
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD
Varna, Bulgaria
Tom Baker Cancer Center
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.